These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23734685)

  • 1. Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer.
    Jiang Q; Zheng S; Wang G
    Future Med Chem; 2013 Jun; 5(9):1023-35. PubMed ID: 23734685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
    Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
    Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal therapy of breast cancer.
    Locker GY
    Cancer Treat Rev; 1998 Jun; 24(3):221-40. PubMed ID: 9767736
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
    Lykkesfeldt AE
    Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
    Dowsett M; Johnston S; Martin LA; Salter J; Hills M; Detre S; Gutierrez MC; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Smith I
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S113-7. PubMed ID: 16113087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathways to tamoxifen resistance.
    Riggins RB; Schrecengost RS; Guerrero MS; Bouton AH
    Cancer Lett; 2007 Oct; 256(1):1-24. PubMed ID: 17475399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tamoxifen resistance.
    Ring A; Dowsett M
    Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen ("Nolvadex"): a review.
    Clemons M; Danson S; Howell A
    Cancer Treat Rev; 2002 Aug; 28(4):165-80. PubMed ID: 12363457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New developments in hormonal therapy for breast cancer].
    Tominaga T
    Gan To Kagaku Ryoho; 1996 May; 23(6):678-83. PubMed ID: 8645017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aromatase inhibitor (AI) in the treatment of breast cancer.
    Irawan C; Abdulmuthalib
    Acta Med Indones; 2005; 37(1):43-8. PubMed ID: 15879638
    [No Abstract]   [Full Text] [Related]  

  • 19. Aromatase inhibitors in early breast cancer treatment.
    Mauriac L; Smith I
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):46-57. PubMed ID: 14513436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.